Celularity, a biotechnology company, went public via a SPAC merger with GX Acquisition, a special purpose acquisition company, in a $1.25bn deal. “We are excited to see Celularity take this very important next step in its evolution as a transformative biotechnology company by becoming a publicly-traded company, listed on The Nasdaq Capital Market under the symbol “CELU”. This step will enable Celularity to continue to leverage the company’s commercial and clinical-stage assets to treat diseases of high unmet need, like cancer, infectious diseases and degenerative diseases,” Dean C. Kehler, GX Acquisition Co-Chairman and CEO.